Pine Valley Investments Ltd Liability Co Purchases 2,287 Shares of Cigna Group $CI

Pine Valley Investments Ltd Liability Co grew its position in shares of Cigna Group (NYSE:CI) by 16.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,858 shares of the health services provider’s stock after acquiring an additional 2,287 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in Cigna Group were worth $4,230,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of CI. DV Trading LLC increased its stake in shares of Cigna Group by 187.5% during the first quarter. DV Trading LLC now owns 920 shares of the health services provider’s stock valued at $245,000 after buying an additional 600 shares during the period. Parallel Advisors LLC lifted its position in Cigna Group by 26.1% during the first quarter. Parallel Advisors LLC now owns 3,568 shares of the health services provider’s stock valued at $952,000 after buying an additional 738 shares during the period. NewEdge Advisors LLC boosted its stake in Cigna Group by 47.8% during the first quarter. NewEdge Advisors LLC now owns 34,277 shares of the health services provider’s stock worth $9,143,000 after acquiring an additional 11,085 shares in the last quarter. Caerus Investment Advisors LLC purchased a new stake in Cigna Group in the first quarter worth about $294,000. Finally, First Nebraska Trust Co bought a new position in shares of Cigna Group during the first quarter valued at approximately $204,000. 86.99% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Cigna Group news, CAO Jamie G. Kates sold 899 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $298.61, for a total transaction of $268,450.39. Following the completion of the sale, the chief accounting officer directly owned 2,368 shares in the company, valued at $707,108.48. The trade was a 27.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO David Cordani sold 201,878 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $292.82, for a total transaction of $59,113,915.96. Following the sale, the chief executive officer directly owned 34,337 shares of the company’s stock, valued at $10,054,560.34. The trade was a 85.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CI. Guggenheim boosted their price target on Cigna Group from $338.00 to $361.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of Cigna Group in a research note on Monday, June 1st. Robert W. Baird set a $362.00 target price on Cigna Group in a report on Friday. Piper Sandler reduced their price target on Cigna Group from $370.00 to $346.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $315.00 price target on shares of Cigna Group in a research report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $341.60.

Cigna Group Stock Up 0.1%

Cigna Group stock opened at $279.27 on Monday. Cigna Group has a 12 month low of $239.51 and a 12 month high of $315.47. The stock has a fifty day simple moving average of $286.62 and a two-hundred day simple moving average of $281.14. The company has a current ratio of 0.76, a quick ratio of 0.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $73.79 billion, a price-to-earnings ratio of 11.55, a PEG ratio of 1.07 and a beta of 0.29.

Cigna Group (NYSE:CI) last announced its quarterly earnings results on Thursday, July 30th. The health services provider reported $7.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.60 by $0.18. The firm had revenue of $70.04 billion for the quarter, compared to the consensus estimate of $70.14 billion. Cigna Group had a return on equity of 19.75% and a net margin of 2.27%.The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the company posted $7.20 earnings per share. Cigna Group has set its FY 2026 guidance at 30.450- EPS. Equities analysts predict that Cigna Group will post 30.5 EPS for the current fiscal year.

Cigna Group Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be given a $1.56 dividend. This represents a $6.24 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 8th. Cigna Group’s payout ratio is 25.82%.

Key Stories Impacting Cigna Group

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna reported adjusted second-quarter earnings of $7.78 per share, above the roughly $7.60 consensus estimate, while revenue rose 7% year over year to approximately $71.7 billion. Cigna Healthcare revenue increased 9%, and Evernorth Health Services revenue grew 6%. Cigna Q2 results and outlook
• Positive Sentiment: Management raised its 2026 adjusted earnings outlook to at least $30.45 per share, implying approximately 10% earnings growth, supported by strength across the healthcare and pharmacy-benefit businesses. Cigna raises annual profit forecast
• Positive Sentiment: Analyst sentiment remains constructive: Barclays raised its price target from $304 to $310 while retaining an “equal weight” rating. A separate analysis highlighted CI’s discounted valuation, ongoing share repurchases, strong cash generation, and $1.56-per-share dividend. Cigna valuation analysis
• Neutral Sentiment: The earnings beat was accompanied by revenue that was slightly below some analyst estimates, and Barclays’ “equal weight” stance suggests the improved outlook may already be partly reflected in the stock.
• Negative Sentiment: Cigna expects lower growth in prescriptions for popular GLP-1 drugs. Because these treatments are a significant growth area for pharmacy services, slower utilization could temper future revenue and profit expansion. Cigna GLP-1 prescription outlook
• Negative Sentiment: Elevated medical costs and higher pharmacy expenses remain industrywide risks. Those pressures may explain why investors initially treated the guidance increase cautiously despite Cigna’s higher profit and broad-based operating growth.

Cigna Group Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.